Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

AbbVie Stock: Analyst Estimates & Ratings

AbbVie Inc. (ABBV) is a worldwide biopharmaceutical company based in North Chicago, Illinois. It conducts research, develops, and supplies advanced medicines for the treatment of challenging conditions in immunology, cancer, neuroscience, ophthalmology, and aesthetics. The company has a market capitalization of $386.47 billion. 

Strong sales from immunology blockbusters Skyrizi and Rinvoq offset Humira’s patent cliff decline. Growth in neuroscience and a diversified portfolio fueled revenue in 2025. Over the past 52 weeks, AbbVie’s stock has gained 25.8%, while over the past six months, it has risen 15.3%. The company’s shares reached a 52-week high of $244.81 in October 2025, but are...

Fundamentals

See More
  • Market Capitalization, $K 389,584,672
  • Shares Outstanding, K 1,767,385
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,034 M
  • EBITDA $ 17,420 M
  • 60-Month Beta 0.36
  • Price/Sales 6.55
  • Price/Cash Flow 14.64
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 29.49% (-0.44%)
  • Historical Volatility 26.04%
  • IV Percentile 84%
  • IV Rank 35.14%
  • IV High 51.27% on 04/08/25
  • IV Low 17.68% on 02/19/25
  • Expected Move (DTE 7) 8.76 (3.93%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 9,658
  • Volume Avg (30-Day) 51,814
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 213,430
  • Open Int (30-Day) 251,532
  • Expected Range 214.03 to 231.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.66
  • Number of Estimates 8
  • High Estimate 2.72
  • Low Estimate 2.62
  • Prior Year 2.16
  • Growth Rate Est. (year over year) +23.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
209.96 +6.18%
on 01/20/26
237.04 -5.95%
on 01/07/26
-6.81 (-2.96%)
since 12/30/25
3-Month
209.96 +6.18%
on 01/20/26
239.29 -6.84%
on 11/13/25
-5.27 (-2.31%)
since 10/30/25
52-Week
164.39 +35.61%
on 04/09/25
244.81 -8.94%
on 10/01/25
+47.28 (+26.92%)
since 01/30/25

Most Recent Stories

More News
AbbVie Stock: Analyst Estimates & Ratings

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

XLV : 154.78 (+0.62%)
$SPX : 6,928.93 (-0.58%)
ABBV : 223.81 (+1.53%)
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

NORTH CHICAGO, Ill. , Jan. 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the launch of Love in Mind ™, an educational initiative that seeks to elevate the conversation about...

ABBV : 223.81 (+1.53%)
Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

ABBV : 223.81 (+1.53%)
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

-  N ine e-posters presenting comprehensive Allergan Aesthetics portfolio data spanning first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA,...

ABBV : 223.81 (+1.53%)
1 Safe-and-Steady Stock on Our Watchlist and 2 We Find Risky

1 Safe-and-Steady Stock on Our Watchlist and 2 We Find Risky

MCY : 87.17 (+0.01%)
STC : 67.18 (-1.07%)
ABBV : 223.81 (+1.53%)
The 3 Most Reliable Dividend Stocks to Buy for Years to Come

These three dividend stocks are long-term winners with dependable payouts.

PEP : 152.96 (+2.87%)
ABBV : 223.81 (+1.53%)
O : 61.01 (+0.83%)
3 “Forever Stocks” to Hold When the Market Won’t Sit Still

Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy

CVX : 176.30 (+2.98%)
MRK : 110.23 (+1.74%)
CL : 90.05 (+5.64%)
ABBV : 223.81 (+1.53%)
AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement.

ABBV : 223.81 (+1.53%)
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NORTH CHICAGO, Ill. , Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE ® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific...

ABBV : 223.81 (+1.53%)
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

NORTH CHICAGO, Ill. , Jan. 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans...

ABBV : 223.81 (+1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 229.85
2nd Resistance Point 227.00
1st Resistance Point 223.71
Last Price 223.81
1st Support Level 217.57
2nd Support Level 214.72
3rd Support Level 211.43

See More

52-Week High 244.81
Last Price 223.81
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar